Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2666MR)

This product GTTS-WQ2666MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2666MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3971MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ769MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ2635MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ4601MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ11506MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ6952MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ9220MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ7462MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW